Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study [0.03%]
Erdafitinib与化疗在抗程序性死亡-配体1治疗后进展的FGF受体改变的晚期或转移性尿路上皮癌中的比较：THOR三期研究中亚洲亚群的探索性分析
Nobuaki Matsubara,Yohann Loriot,Earle F Burgess et al.
Nobuaki Matsubara et al.
Introduction: The randomized phase 3 THOR study showed significantly longer survival with erdafitinib (pan-fibroblast growth factor receptor [FGFR] inhibitor) over chemotherapy in adults with FGFR-altered locally advanced...
Symptom Clusters and Social Support in Patients With Lung Cancer Undergoing Anti-Programmed Death 1/Programmed Death Ligand 1 Immunotherapy: A Cross-sectional Analysis [0.03%]
接受抗程序性死亡1 /程序性死亡配体1免疫治疗的肺癌患者的症状群和社会支持：横断面分析
Jinling Guo,Yanzhu Qin,Caixia Li et al.
Jinling Guo et al.
Background: Anti-programmed death 1/programmed death ligand 1 immunotherapy has greatly advanced lung cancer treatment; however, the symptom clusters experienced by patients during immunotherapy, their influencing factors...
Anti-programmed death-1 immunotherapy-promising treatment for metastatic colorectal cancer: A case report [0.03%]
抗程序性死亡-1免疫治疗作为转移性结直肠癌的治疗方案一例报告
Tian-Hao Guo,Sheng-Wei Hong,Wen-Jian Zhu et al.
Tian-Hao Guo et al.
Background: Colorectal cancer (CRC) is the third most prevalent form of cancer worldwide. Among patients with CRC, colorectal liver metastasis (CRLM) is the foremost direct contributor to mortality. In recent years, immun...
A combination treatment with a water extract from Euglena gracilis and anti-PD-1 antibody strongly inhibits growth of lung cancer in mice through stimulating tumor-infiltrating lymphocytes [0.03%]
一种眼状体(Euglena gracilis)水提取物与抗程序性死亡-1抗体联合治疗通过刺激肿瘤浸润淋巴细胞显著抑制小鼠肺癌生长
Susumu Ishiguro,Sarah Devader,Caden Blake et al.
Susumu Ishiguro et al.
Here, we investigated the relationship between the attenuation of lung cancer growth due to oral administration of Euglena gracilis water extract (EWE) and T cell stimulation. Orally administered EWE was revealed to increase PD-1 and PD-L1 ...
Thyroid autoantibodies at baseline predict longer survival in non-small cell lung cancer patients treated with anti-programmed cell death-1 blockade: a prospective study [0.03%]
基线甲状腺自身抗体可预测抗程序性死亡-1阻断治疗非小细胞肺癌患者的长期生存：一项前瞻性研究
Takayuki Okuji,Shintaro Iwama,Tomoko Kobayashi et al.
Takayuki Okuji et al.
The presence of anti-thyroid antibodies (ATAs) is a biomarker for the development of thyroid dysfunction induced by anti-programmed cell death-1 antibodies (PD-1-Abs). While patients with thyroid dysfunction reportedly showed better overall...
Efficacy and safety of anti-programmed death-1 antibody-based combination therapy in advanced or metastatic gastric or gastroesophageal junction cancer in Chinese patients: A real-world study [0.03%]
基于抗程序性死亡-1抗体的联合治疗在中国晚期或转移性胃及胃食管交界部癌患者中的疗效和安全性：一项真实世界研究
Yifan Gao,Haoqian Li,Lei Qiu et al.
Yifan Gao et al.
Purpose: Programmed death-1 antibody plus chemotherapy has gained approval for the treatment for (human epidermal growth factor receptor 2 negative locally advanced or metastatic gastric or gastroesophageal junction cance...
Synergistic action of gemcitabine and celecoxib in promoting the antitumor efficacy of anti-programmed death-1 monoclonal antibody by triggering immunogenic cell death [0.03%]
吉西他滨和塞来昔布联合促进抗程序性死亡-1单克隆抗体疗效的协同作用机制：通过诱发免疫原性细胞死亡诱导肿瘤凋亡
Xiongjie Zhu,Wenkai Zhang,Zhongjian Yu et al.
Xiongjie Zhu et al.
Background: Emerging evidence suggests that immunogenic chemotherapy not only kills tumor cells but also improves the immune-suppressive tumor microenvironment by inducing immunogenic cell death (ICD), leading to sustaine...
Multimode Ultrasound Model for Predicting the Early Treatment Response of Anti-VEGF Agents Plus Anti-PD-1 Antibody in Patients with Unresectable Hepatocellular Carcinoma [0.03%]
抗血管内皮生长因子联合抗程序性死亡-1抗体治疗不可切除肝细胞癌患者的早期疗效声学多模态模型预测
Zi-Nan Liang,Hong Wang,Wen-Chao Cui et al.
Zi-Nan Liang et al.
Objective: The purpose of the study described was to establish prediction models to initially screen the beneficiary patients with unresectable hepatocellular carcinoma (HCC) in the treatment of anti-vascular endothelial ...
Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report [0.03%]
抗程序性死亡-1抗体治疗过程中出现似Vogt-小柳-原田病葡萄膜炎1例报告
Jia-Ning Wang,Yue Zhang,Chen-Ye Huang et al.
Jia-Ning Wang et al.
Background: Several immune checkpoint inhibitors (ICIs) have been linked to the occurrence of Vogt-Koyanagi-Harada disease (VKHD)-like uveitis. Among the ICIs, there has been no report of immune-related adverse events (ir...
Case Reports
BMC ophthalmology. 2024 Jun 7;24(1):240. DOI:10.1186/s12886-024-03484-9 2024
PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC [0.03%]
抗PD1治疗头颈鳞癌的生物标志物检测PD-L1功能状态
Bar Kaufman,Tarek Taha,Orli Abramov et al.
Bar Kaufman et al.
Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy remains a clinical challenge. This study evaluated the functional bin...
耗时 0.16246 秒，为您在
48206918
条记录里面共找到 126 篇文章 [XML]